Beam Therapeutics BEAM Investment Income Net Amortization Of Discount And Premium
Investment Income Net Amortization Of Discount And Premium at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's investment income net amortization of discount and premium.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's investment income net amortization of discount and premium?
- Beam Therapeutics (BEAM) reported investment income net amortization of discount and premium of $2.76M in Q1 2026.
- How has Beam Therapeutics's investment income net amortization of discount and premium changed year-over-year?
- Beam Therapeutics's investment income net amortization of discount and premium decreased by 28.2% year-over-year, from $3.85M to $2.76M.
- What is the long-term trend for Beam Therapeutics's investment income net amortization of discount and premium?
- Over 4 years (2021 to 2025), Beam Therapeutics's investment income net amortization of discount and premium has grown at a 281.9% compound annual growth rate (CAGR), from $75K to $15.96M.
- What does investment income net amortization of discount and premium mean?
- Represents the net impact of interest income earned on investments adjusted for the amortization of premiums or discounts on debt securities. This metric reflects the non-operating yield generated from the company's cash and investment portfolio. It is a key indicator of how effectively the company manages its idle capital to generate supplemental returns.